SMS Lifesciences India (SMS) has agreed to acquire Mahi Drugs Private Limited.

Based in India, the acquirer company is involved in product manufacturing, while the target company, also based in India, is a manufacturer of active pharmaceutical ingredients (APIs).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Merck & Co has signed an agreement to acquire Viralytics through its subsidiary.

Viralytics will become a subsidiary of Merck, upon completion of the transaction in Q2 2018.

Merck will obtain full rights to Viralytics’s investigational oncolytic immunotherapy CAVATAK (CVA21), as part of the transaction.

Based in the US, Merck is a biopharmaceutical company, while Viralytics is an Australian oncolytic immunotherapies developer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Merck & Co has signed an agreement to acquire Viralytics through its subsidiary.”

Merck has appointed Credit Suisse Securities (USA) as financial advisor, and Baker & McKenzie as legal advisor, while Viralytics selected Lazard as financial advisor and McCullough Robertson as legal advisor for the transaction.

Pharmaceutical company Teijin has agreed to purchase a controlling interest in medical device provider MedTech Heart from venture capital firm Seeds Rocket.

Teijin also will acquire MedTecHeart, a subsidiary of the MedTech Heart, as part of the transaction.

The two companies will be incorporated into a new entity named Teijin MedTecHeart.

Both the acquirer and target companies are based in Japan.